Moreover, ablation of CD44 (a gastric cancer stem cell marker [188]) in K19-Wnt1/C2mE mice (i.e., CD44−/−K19-Wnt1/C2mE mice) suppressed gastric tumor growth [189], suggesting that CD44-targeted therapy may impair tumor growth ability. The gene discussed is KRT19; the disease is gastric neoplasm.